High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation

References

• Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;113:3931–3937.
   PubMed Web of Science ®Google Scholar
• Ai WZ, Chang ET, Fish K, et al. Racial patterns of extranodal natural killer/T-cell lymphoma, nasal type, in California: a population-based study. Br J Haematol 2012;156:626–632.
   PubMed Web of Science ®Google Scholar
• Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004;103:216–221.
   PubMed Web of Science ®Google Scholar
• Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004;100:366–375.
   PubMed Web of Science ®Google Scholar
• Pagano L, Gallamini A, Trape G, et al. NK/T-cell lymphomas ‘nasal type’: an Italian multicentric retrospective survey. Ann Oncol 2006;17:794–800.
   PubMed Web of Science ®Google Scholar
• Ho FC, Srivastava G, Loke SL, et al. Presence of Epstein-Barr virus DNA in nasal lymphomas of B and ‘T’ cell type. Hematol Oncol 1990;8:271–281.
   PubMed Web of Science ®Google Scholar
• Fox CP, Shannon-Lowe C, Rowe M. Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. Herpesviridae 2011;2:8.
   PubMedGoogle Scholar
• Kim BS, Kim TY, Kim CW, et al. Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy – result of chemotherapy in NK/T-cell lymphoma. Acta Oncol 2003;42:779–783.
   PubMed Web of Science ®Google Scholar
• Drenou B, Lamy T, Amiot L, et al. CD3- CD56 + non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 1997;89:2966–2974.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995;76:2351–2356.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• Sakata K, Fuwa N, Kodaira T, et al. Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol 2006;79:179–184.
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, et al. Early stage nasal NK/ T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002;54: 182–190.
   PubMed Web of Science ®Google Scholar
• Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181–189.
   PubMed Web of Science ®Google Scholar
• Liang R. Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type. Br J Haematol 2009;147: 13–21.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 2009;27:6027–6032.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009;27:5594–600.
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612–618.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 2012;120:2973–2980.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Kwong YL, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008;99:1016–1020.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Petit B, Girault S, et al. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 2009;20: 110–116.
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhang Y, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 2003;78:163–167.
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhu J, et al. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 2009;88:647–652.
   PubMed Web of Science ®Google Scholar
• Liang R, Chen F, Lee CK, et al. Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. Bone Marrow Transplant 1997;19:91–93.
   PubMed Web of Science ®Google Scholar
• Au WY, Lie AK, Liang R, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003;14:1673–1676.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Bang SM, Lee J, et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant 2006;37:819–824.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Suzumiya J, Nakamura S, et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 2006;37:425–431.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Krenacs L, Kumar S, et al. Extranodal peripheral T-cell and NK-cell neoplasms. Am J Clin Pathol 1999;111(1 Suppl. 1):S46–55.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 1999; 111(1 Suppl. 1):S8–12.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Geneva: WHO Press; 2008.
   Google Scholar
• Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 2011;117:1834–1839.
   PubMed Web of Science ®Google Scholar
• Kwong YL. High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant 2009;44:709–714.
   PubMed Web of Science ®Google Scholar
• Lee J, Au WY, Park MJ, et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 2008;14:1356–1364.
   PubMed Web of Science ®Google Scholar
• Takenaka K, Shinagawa K, Maeda Y, et al. High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56 + natural killer cell lymphomas. Leuk Lymphoma 2001;42:1297–1303.
   PubMed Web of Science ®Google Scholar
• d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;305:3093–3099.
   Web of Science ®Google Scholar